Sign In
Buy AXSM
$212.17
+1.13 (+0.535%)
At Close: Aug 04, 2026
Axsome Therapeutics (NASDAQ:AXSM) Reaches New 12-Month High – Here’s Why
03:32am, Sunday, 21'st Dec 2025
Axsome Therapeutics, Inc. (NASDAQ: AXSM - Get Free Report) reached a new 52-week high during trading on Friday. The stock traded as high as $154.49 and last traded at $151.96, with a volume of 183511
Assenagon Asset Management S.A. Raises Stock Holdings in Axsome Therapeutics, Inc. $AXSM
03:24am, Friday, 19'th Dec 2025
Assenagon Asset Management S.A. increased its stake in shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM) by 62.9% in the undefined quarter, according to its most recent disclosure with the Securities
Axsome Therapeutics, Inc. (AXSM) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
06:18pm, Thursday, 04'th Dec 2025
Axsome Therapeutics, Inc. (AXSM) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Axsome (AXSM) Up 5.3% Since Last Earnings Report: Can It Continue?
12:31pm, Wednesday, 03'rd Dec 2025
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
2 Under-the-Radar Stocks to Buy Heading Into 2026
08:06pm, Monday, 01'st Dec 2025
Axsome Therapeutics boasts a deep late-stage pipeline with billions in potential revenue opportunity. Exelixis' core franchise remains strong while it develops promising new medicines.
Axsome Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Thursday, 20'th Nov 2025
NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an
Envestnet Asset Management Inc. Grows Stake in Axsome Therapeutics, Inc. $AXSM
04:58am, Sunday, 16'th Nov 2025
Envestnet Asset Management Inc. grew its stake in shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM) by 12.4% in the second quarter, according to its most recent filing with the Securities and Exchang
2 Monster Stocks in the Making
04:45am, Monday, 10'th Nov 2025
Viking Therapeutics is developing innovative medicines in a fast-growing area. Axsome Therapeutics is generating strong sales, and solid regulatory progress could improve things.
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics
07:00am, Thursday, 06'th Nov 2025
MIAMI, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy
07:00am, Thursday, 06'th Nov 2025
Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABA A α2,3 receptor positive allosteric modulator
Axsome: Alzheimer's Disease Agitation sNDA Adds Optionality, Not A Thesis Changer
03:12pm, Wednesday, 05'th Nov 2025
Axsome Therapeutics remains a 'Sell' due to an undifferentiated CNS pipeline, heavy SG&A, and ongoing net losses despite revenue growth. Auvelity's sales growth appears largely marketing-driven and co
AXSM Q3 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales
11:30am, Tuesday, 04'th Nov 2025
Axsome incurs wider-than-expected Q3 loss but revenues soar 63% on booming Auvelity sales, with Sunosi and the newest drug, Symbravo, aiding the top line.
Axsome Therapeutics, Inc. (AXSM) Q3 2025 Earnings Call Transcript
02:46pm, Monday, 03'rd Nov 2025
Axsome Therapeutics, Inc. ( AXSM ) Q3 2025 Earnings Call November 3, 2025 8:00 AM EST Company Participants Darren Opland - Director of Corporate Communications Herriot Tabuteau - Founder, Chairman, CE
Axsome Therapeutics (AXSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
11:00am, Monday, 27'th Oct 2025
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Halper Sadeh LLC Encourages Axsome Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights
11:20am, Friday, 24'th Oct 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Axsome Therapeutics, Inc. (NASDAQ: AXSM) breached their fiduciary d
